Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Craig M. Goodwin(University of North Carolina at Chapel Hill), Channing J. Der(University of North Carolina at Chapel Hill), Clint A. Stalnecker(University of North Carolina at Chapel Hill), Adrienne D. Cox(University of North Carolina at Chapel Hill), Valerie Calvert(George Mason University), Kristina Drizyte‐Miller(University of North Carolina at Chapel Hill), Bjoern Papke(University of North Carolina at Chapel Hill), Irem Ozkan‐Dagliyan(University of North Carolina at Chapel Hill), Elisa Baldelli(Abterra Biosciences (United States)), Natalie Bublitz(German Cancer Research Center), Andrew M. Waters(University of North Carolina at Chapel Hill), Sehrish Javaid(University of North Carolina at Chapel Hill), Andrew P. Beelen(United Therapeutics (United States)), Kris C. Wood(Duke University), Mareen Lüthen(Unknown), Jessica A. Sorrentino(University of North Carolina at Chapel Hill), Mariaelena Pierobon(George Mason University), Kirsten L. Bryant(University of North Carolina at Chapel Hill), Amber M. Amparo(University of North Carolina at Chapel Hill), Autumn J. McRee(University of North Carolina at Chapel Hill), Runying Yang(University of Alberta), Jennifer E. Klomp(Michigan State University), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Christine Sers(Charité - Universitätsmedizin Berlin)
Cited by 0
Related Papers
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
|Journal of Clinical Investigation|2014|717
Rho-family GTPases: it's not only Rac and Rho (and I like it)
|Journal of Cell Science|2004|594